Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jun 28, 2009; 15(24): 3015-3024
Published online Jun 28, 2009. doi: 10.3748/wjg.15.3015
Published online Jun 28, 2009. doi: 10.3748/wjg.15.3015
Table 4 Demographic data, clinical condition, and laboratory parameters before treatment in survivors and non-survivors treated with MARS
| ALF | AOCLF | |||||
| Transplant-free survivors | Non-survivors and transplant recipients | P | Transplant-free survivors | Non-survivors and transplant recipients | P | |
| Demographic and clinical data at baseline | ||||||
| Number of patients (n) | 54 | 59 | 9 | 53 | ||
| Age, years (range) | 39 (14-81) | 50 (19-71) | < 0.0001 | 52 (30-58) | 52 (16-75) | NS |
| Sex, male % (n) | 52 (28) | 31 (18) | 0.021 | 67 (6) | 62 (33) | NS |
| BMI, kg/m2 | 24 (16.9-39.7) | 27 (17-40) | NS | 32 (18-38) | 26 (20-56) | NS |
| MARS sessions/patient | 2 (1-5) | 3 (1-12) | < 0.0001 | 1 (1-3) | 2 (1-13) | NS |
| Mechanical ventilation used % (n) | 20 (11) | 44 (26) | 0.007 | 33 (3) | 32 (17) | NS |
| Vasoactive-medication used % (n) | 28 (15) | 34 (20) | NS | 33 (3) | 60 (32) | NS |
| Renal insufficiency % (n) | 32 (17) | 39 (23) | NS | 56 (5) | 66 (35) | NS |
| MELD score (range) | 24 (5-48) | 32 (7-50) | < 0.0001 | 28 (17-48) | 37 (25-52) | 0.08 |
| Encephalopathy grade prior to treatment | 0 (0-4) | 3 (0-4) | < 0.0001 | 1 (0-4) | 1 (0-4) | NS |
| Laboratory values at baseline | ||||||
| Hemoglobin g/L | 113 (78-170) | 106 (74-160) | NS | 106 (80-127) | 99 (59-130) | NS |
| Leucocytes 109/L | 8.3 (1-23.4) | 9.1 (2.6-41) | 0.045 | 9.7 (1.4-35.3) | 15.5 (1.6-39.3) | NS |
| Platelets 109/L | 146 (11-351) | 130 (37-511) | NS | 131 (69-383) | 107 (15-508) | NS |
| CRP g/L | 10 (5-331) | 8 (5-153) | NS | 28 (8-58) | 35 (5-110) | NS |
| Creatinine &mgr;mol/L | 77 (35-1318) | 91 (36-567) | NS | 128 (56-556) | 210 (29-686) | NS |
| Urea mmol/L | 5.2 (1.1-31.2) | 7.8 (0.8-29.3) | NS | 8.4 (2.3-39.6) | 17.45 (1.8-56.5) | NS |
| NH4-ion &mgr;mol/L | 50 (8-512) | 99 (24-389) | < 0.0001 | 66 (12-241) | 75 (19-311) | NS |
| Bilirubin &mgr;mol/L | 71 (4-761) | 425 (8-694) | < 0.0001 | 455 (17-745) | 514 (143-909) | NS |
| AST U/L | 732 (15-24 360) | 497 (50-20900) | NS | 214 (27-2030) | 164 (31-4540) | NS |
| ALT U/L | 1165 (11-12 500) | 708 (71-10 890) | NS | 69 (9-2904) | 87 (10-897) | NS |
| γ-GT U/L | 61 (8-503) | 109.5 (20-2139) | 0.013 | 230 (44-398) | 109 (19-1086) | NS |
| FV % | 51 (7-201) | 31 (5-101) | 0.012 | 65 (41-124) | 48 (7-125) | 0.028 |
| AT3 % | 52 (15-125) | 27 (15-110) | < 0.0001 | 40 (15-100) | 29.5 (13-88) | 0.043 |
| TT (%) | 26 (6-80) | 16 (6-49) | < 0.0001 | 26 (9-96) | 21 (6-135) | NS |
| INR | 2.3 (1.1-7.7) | 3.2 (1.4-9.9) | < 0.0001 | 2 (1-4.3) | 2.4 (1-8.5) | NS |
| Albumin g/L | 29.9 (19.2-46.4) | 24.8 (11.5-41.2) | < 0.0001 | 23.3 (13.6-31.8) | 21.8 (14.7-32.7) | NS |
- Citation: Kantola T, Koivusalo AM, Parmanen S, Höckerstedt K, Isoniemi H. Survival predictors in patients treated with a molecular adsorbent recirculating system. World J Gastroenterol 2009; 15(24): 3015-3024
- URL: https://www.wjgnet.com/1007-9327/full/v15/i24/3015.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.3015